Search Bar & Filters
Found 15 Actively Recruiting clinical trials
Actively Recruiting
Researchers are investigating new treatments for high-risk, early-stage breast cancer, focusing on triple-negative breast cancer TNBC and hormone receptor-low positiveHER2-negative breast cancer. These types are defined by low or absent HER2 protein and hormone receptors. The study aims to evaluate whether adding sacituzumab tirumotecan sac-TMT, a targeted therapy, to pembrolizumab and chemotherapy improves outcomes compared to pembrolizumab plus chemotherapy alone. Participants are randomly assigned to one of two groups. One group receives sac-TMT intravenously every two weeks with pembrolizumab every three weeks for 12 weeks, followed by pembrolizumab combined with carboplatin and paclitaxel for another 12 weeks, surgery, optional radiation, and additional pembrolizumab for up to 28 weeks. The other group receives carboplatin and paclitaxel with pembrolizumab for 6 weeks, followed by pembrolizumab combined with cyclophosphamide and either doxorubicin or epirubicin for up to 12 weeks, surgery, optional radiation, and pembrolizumab for up to 28 weeks. Additional adjuvant treatments may be given to participants with residual disease. During the study, participants undergo assessments including tumor biopsies, surgery, and optional radiation therapy. Researchers monitor outcomes such as the percentage of participants with no detectable cancer at surgery and event-free survival over up to 92 months. Secondary measures include overall survival, quality of life, side effects, and adverse events. The total study duration may extend up to nearly 10 years to monitor long-term effects and safety.
Actively Recruiting
Researchers are evaluating a new medication called VH4524184 for treating adults with HIV-1 who have never received treatment before. This Phase 2b study compares two doses of VH4524184, each taken with the medications emtricitabine and tenofovir alafenamide FTCTAF, against a standard HIV treatment combining dolutegravir and lamivudine DTG3TC. The goal is to collect long-term data on the antiviral activity of VH4524184 and to understand the best dosing for future studies. Participants are assigned to one of several groups one group receives a low dose of VH4524184 plus FTCTAF daily for 12 months, another group receives a high dose of VH4524184 plus FTCTAF daily for 12 months, and a third group takes DTG and 3TC daily for 24 months. After 12 months, those on VH4524184 may continue with a selected dose combined with FTCTAF daily until month 24. All medications are taken orally. During the study, participants attend scheduled visits for assessments including blood tests to measure HIV-1 RNA levels, CD4 T-cell counts, and drug concentrations. Researchers monitor the percentage of participants achieving viral suppression at 12 months and maintain it through 24 months. Safety is closely observed through tracking adverse events until roughly month 36. The total participation time may span up to 36 months to evaluate the long-term effects and safety of the treatments.
Actively Recruiting
Researchers are evaluating Dostarlimab compared to a placebo in adults with locally advanced unresected Head and Neck Squamous Cell Carcinoma HNSCC. This phase 3 trial aims to assess the safety and effectiveness of Dostarlimab as a sequential therapy following chemoradiation treatment in participants with this type of cancer. Participants are randomly assigned to receive either Dostarlimab or a placebo, both given as intravenous infusions. The study is double-blind, meaning neither the participants nor the researchers know which treatment is being given. The treatments follow completion of chemoradiation with cisplatin and radiotherapy intended to cure the cancer. During the study, participants will be monitored for up to approximately 5 years. Researchers will evaluate event-free survival and overall survival, with safety assessments including treatment-emergent adverse events and laboratory tests. Blood samples will be taken to measure drug levels and immune responses. This long-term follow-up will help understand the effects and safety of Dostarlimab after chemoradiation therapy.
Actively Recruiting
Researchers are evaluating the clinical effectiveness and safety of icotrokinra in adults with moderately to severely active Crohns disease, a long-term condition causing serious inflammation in the intestines. The study is a Phase 2b3 randomized, double-blind, placebo-controlled trial aiming to better understand how well icotrokinra works in treating this condition. Participants will receive one of several oral treatments daily during an initial 12-week induction phase either one of two doses of icotrokinra or a matching placebo. After Week 12, their response status will guide further treatment. Those responding to icotrokinra may be randomized to maintenance doses for up to 40 weeks, with some eligible to join a long-term extension study. Placebo recipients who respond may continue placebo or switch to icotrokinra under specific conditions. Throughout the trial, participants will undergo regular assessments to monitor clinical response, remission, and endoscopic healing at Weeks 12 and 40. Safety will be closely followed up to four weeks after the last dose. The study measures various outcomes including patient-reported remission, inflammatory markers, quality of life, and fatigue. Total participation may extend up to several months depending on treatment phase and eligibility for long-term follow-up.
Actively Recruiting
Researchers are evaluating the addition of Tersolisib LY4064809STX-478 to other anti-cancer drugs as a first treatment for adults with advanced hormone receptor-positive HR and human epidermal growth factor receptor 2-negative HER2- breast cancer that has a PIK3CA genetic mutation. The study aims to assess the effectiveness and safety of this combination in people whose cancer cannot be cured by surgery alone. Participants may continue in the study as long as the treatment is helping and side effects are manageable. Participants will be randomly assigned to one of three groups two different doses of Tersolisib combined with a CDK46 inhibitor and endocrine therapy ET, or a placebo combined with the same drugs. The CDK46 inhibitor and ET are given orally or intramuscularly depending on the drug chosen by the investigator. Treatments are administered orally or by injection as appropriate. The study includes a phase 2 dose optimization portion and a phase 3 randomized, double-blind, placebo-controlled portion. During the study, participants will undergo regular assessments including scans and tests to measure tumor response and progression. Researchers will monitor overall response rate, progression-free survival, and other health outcomes for up to 5 to 7 years. Safety and drug levels in the blood will also be tracked. Participants quality of life and physical function will be evaluated using questionnaires. The total time in the study depends on individual treatment response and side effects.
Actively Recruiting
Researchers are evaluating the effectiveness and safety of KarXT in adult Japanese participants who are experiencing acute psychotic episodes of schizophrenia. This Phase 3 randomized study focuses on adults aged 18 to 65 with a confirmed diagnosis of schizophrenia based on DSM-5 criteria. The study aims to better understand how KarXT affects symptoms and overall severity of schizophrenia. Participants are assigned to receive either KarXT or a placebo in a double-blind, placebo-controlled manner for 5 weeks. After this period, a 52-week open-label extension allows all participants to receive KarXT to further assess long-term safety and effectiveness. Dosing follows specified schedules, and the study monitors changes in symptoms and adverse events throughout both phases. During the trial, participants will have regular assessments including symptom rating scales like the Positive and Negative Syndrome Scale PANSS and Clinical Global Impressions-Severity CGI-S. Safety evaluations include monitoring adverse events, physical exams, vital signs, laboratory tests, ECGs, and assessments for side effects such as movement disorders and suicidal ideation. The total study duration may extend up to about one year, including both the initial double-blind and the extension phases.
Actively Recruiting
Researchers are evaluating mocertatug rezetecan Mo-Rez in treating endometrial cancer EC compared to standard chemotherapy options. The study aims to understand how well Mo-Rez works and how safe and tolerable it is for participants, including comparing side effects between Mo-Rez and standard treatments. This is a phase 3 randomized, open-label study focusing on treatment after prior platinum-based chemotherapy and immunotherapy. Participants will receive either mocertatug rezetecan or standard of care chemotherapy, which includes paclitaxel or doxorubicin, based on the investigators choice. The study uses a parallel design to compare these treatments directly. Treatment and assessments will continue for up to about 97 weeks for primary outcomes, with longer follow-up for secondary outcomes up to approximately 156 weeks. Throughout the study, participants will undergo multiple evaluations, including tumor response assessments by blinded independent central review and investigator assessments. Researchers will monitor progression-free survival, overall survival, treatment side effects, and quality of life using specialized questionnaires. Laboratory tests, vital signs, ECGs, and antibody measurements against the study drug will also be performed. The total participation time may extend over several years to capture long-term outcomes and safety data.
Actively Recruiting
Researchers are studying Mocertatug rezetecan Mo-Rez to see how it works in treating ovarian cancer that does not respond well to platinum-based therapies. This Phase 3 trial compares Mo-Rez to standard chemotherapy treatments while evaluating its safety, tolerability, and side effects. The study is sponsored by GlaxoSmithKline and focuses on platinum-resistant ovarian cancer, including specific tumor types confirmed by tissue testing. Participants will be randomly assigned to receive either Mo-Rez or one of several standard chemotherapy options chosen by their doctor, including Paclitaxel, Pembrolizumab with or without Bevacizumab, Pegylated liposomal doxorubicin PLD, Topotecan, or Gemcitabine. The treatments will be given according to standard administration methods, and participants may continue in the study for up to approximately 212 weeks to evaluate long-term outcomes. Throughout the study, participants will undergo regular assessments including tumor scans to measure disease progression and response, blood tests, and quality-of-life questionnaires. Researchers will monitor survival rates, side effects, vital signs, laboratory values, and immune responses to the drug. Safety monitoring and patient-reported outcomes will continue for the full duration of participation, which may last over four years.
Actively Recruiting
Researchers are evaluating the efficacy and safety of a medicine called NNC0487-0111 in adults with overweight or obesity who also have moderate-to-severe obstructive sleep apnoea OSA treated with positive airway pressure. This Phase 3 study compares NNC0487-0111 to a placebo to see how well it helps reduce body weight and improve sleep apnoea symptoms over time. Participants will be randomly assigned to receive one of these treatments, which are injected under the skin weekly. Participants will receive either one of two dose levels of NNC0487-0111 or a matching placebo injection once a week. Both groups will also follow a reduced-calorie diet and increase physical activity as part of the study. The injections are given using pre-filled pen-injectors at areas such as the thigh, abdomen, or upper arm. The treatment period lasts up to 80 weeks, during which body weight and sleep apnoea severity are closely monitored. Throughout the study, participants will have regular assessments to measure changes in body weight, apnoea-hypopnoea index AHI, sleep quality, blood pressure, blood sugar, cholesterol, and other health markers. Safety is monitored by tracking adverse events until week 84. The study also evaluates improvements in sleep-related symptoms and the potential to reduce or stop positive airway pressure therapy. Total participation may last up to 84 weeks, including follow-up for safety and health outcomes.
Actively Recruiting
Researchers are evaluating the early use of empagliflozin, taken once daily by mouth, in patients hospitalized with acute heart failure who are at high risk of complications. This Phase 3, multicenter, randomized, double-blind trial compares empagliflozin to a placebo to assess its safety and effectiveness. The study is sponsored by Juntendo University and focuses on important outcomes like death, rehospitalization, worsening heart failure, and urine output within 90 days of treatment. Participants will be randomly assigned to receive either empagliflozin 10 mg once daily or a matching placebo. Treatment begins within 12 hours of hospital presentation. Both groups will be closely monitored during hospitalization and for up to 90 days after starting the study drug. The study uses a quadruple-blind design, meaning patients, caregivers, investigators, and assessors do not know which treatment is given. During the study, participants will undergo various assessments including monitoring of heart failure symptoms, urine output, blood tests for heart and kidney function, and quality of life questionnaires. Researchers will measure outcomes such as death rates, heart failure rehospitalizations, symptom changes, and kidney function over 90 days. Safety will be closely tracked throughout the study period. Total participation time varies but includes hospital stay and follow-up visits up to 90 days.
1-10 of 15
1